How Solid Dosage Forms Affect Peptide Release

Solid peptide dosage forms can alter when, where, and how a peptide becomes available for dissolution and transport testing. Tablets, capsules, pellets, granules, films, powders, and multiparticulate systems may use coatings, compression, polymers, porous carriers, pH-responsive materials, or embedded formulation components to control exposure to gastrointestinal conditions. Evaluation must separate dosage-form disintegration, peptide release, peptide dissolution, structural stability, and permeability because completion of one stage does not establish completion of the next.

Solid dosage-form research is one part of the wider investigation into future oral peptide-delivery platforms. Solid forms may simplify handling or create region-specific release patterns, but their performance depends on the complete formulation, manufacturing process, storage conditions, and test environment.

This article is provided for general educational purposes and explains formulation, delivery, and research concepts associated with oral peptide delivery. It does not establish the regulatory status of any specific InStrips product or determine whether a particular product is appropriate for any person.

Disintegration or peptide release from a solid dosage form does not establish peptide stability, epithelial transport, reproducible exposure, or performance outside the exact formulation and experimental conditions studied.

What Is a Solid Peptide Dosage Form?

A solid peptide dosage form is a prepared system in which the peptide and associated formulation components are incorporated into a predominantly solid physical structure.

Experimental solid formats may include:

• compressed tablets
• powder-filled capsules
• coated capsules
• granules
• pellets
• mini-tablets
• multiparticulate systems
• porous carrier systems
• solid films or inserts

These formats can differ in size, internal structure, surface area, mechanical strength, water uptake, disintegration, and release behavior.

Why Solid Forms Are Studied

A solid form may provide a defined physical arrangement for the peptide and other formulation components.

Researchers may investigate solid dosage forms to examine:

• protection from humidity or direct fluid contact
• delayed exposure to selected pH conditions
• release at a selected gastrointestinal region
• separation of incompatible components
• controlled contact between the peptide and an enhancer
• storage stability
• manufacturing consistency

These objectives are formulation hypotheses that require measurement in the final dosage form.

Disintegration and Dissolution Are Different

Disintegration describes the physical breakup of a tablet, capsule, pellet, or other solid structure into smaller pieces.

Dissolution describes movement of a substance from the solid material into the surrounding liquid phase.

A dosage form may:

• disintegrate rapidly while the peptide dissolves slowly
• remain physically intact while releasing dissolved peptide through pores
• break into granules that continue to retain the peptide
• release some components before others
• leave undissolved peptide-associated material

Visual breakup should not be reported as complete peptide dissolution unless the peptide has been measured in the surrounding medium.

Release Is Broader Than Dissolution

Release refers to the peptide leaving the dosage form or becoming available outside its original solid matrix.

The released peptide may be:

• fully dissolved
• partially dissolved
• associated with particles
• contained in colloidal structures
• bound to another formulation component
• present as a precipitated complex

A release measurement should identify what fraction was measured and how dissolved, particulate, associated, and precipitated material were distinguished.

Tablet Compression

Tablets are formed by applying pressure to powders, granules, or other prepared materials.

Compression may change:

• porosity
• particle contact
• water penetration
• disintegration time
• peptide aggregation
• interaction among excipients
• mechanical strength

Higher compression force can produce a stronger tablet while reducing pore space and delaying fluid movement into the dosage form.

The effect depends on the peptide, excipients, particle sizes, moisture, and manufacturing method.

Compression and Peptide Structure

Peptides can respond to mechanical stress differently depending on their sequence, physical form, water content, and surrounding materials.

Researchers may examine whether compression is associated with:

• aggregation
• particle deformation
• changes in crystallinity
• changes in secondary structure
• loss during extraction
• formation of degradation products

A tablet retaining the expected peptide mass does not necessarily establish that the peptide remains in its original structural state.

Powder-Filled Capsules

A powder-filled capsule may contain the peptide alone or mixed with fillers, stabilizers, pH modifiers, enzyme-related components, permeability-related components, lubricants, and flow aids.

Capsule performance may depend on:

• shell composition
• shell thickness
• powder flow
• powder packing
• moisture transfer
• electrostatic behavior
• interactions between the fill and shell

Opening of the capsule shell does not establish uniform dispersion or release of the peptide-containing powder.

Capsule-Shell Materials

Capsule shells may be manufactured from different polymeric materials.

Shell composition can influence:

• water uptake
• mechanical properties
• opening time
• response to pH
• sensitivity to humidity
• interaction with the fill material
• behavior after storage

Results from one capsule-shell material should not be assumed to represent another shell with a different composition or manufacturing process.

Enteric Coatings

Enteric coatings are designed to remain comparatively intact under selected acidic conditions and dissolve or become more permeable under later pH conditions.

Researchers may evaluate:

• resistance during acid-stage testing
• time to coating opening
• pH threshold
• coating thickness
• defects or cracks
• peptide leakage before opening
• release after transfer to another medium

Passing an acid-resistance test does not establish release at one precise location in a variable gastrointestinal environment.

pH-Responsive Release

A pH-responsive material may change solubility, swelling, porosity, or charge as the surrounding pH changes.

Its behavior can also be affected by:

• buffer capacity
• fluid volume
• ionic strength
• agitation
• food-related components
• coating thickness
• storage conditions

The same coating may open at different times in test media that have the same nominal pH but different buffer compositions.

Time-Dependent Release

Some solid systems use polymer erosion, swelling, diffusion, or gradual water penetration to produce time-dependent release.

Release timing may depend on:

• polymer type
• polymer molecular weight
• tablet geometry
• surface area
• porosity
• fluid movement
• mechanical stress

A fixed release time measured in one apparatus does not establish the same timing under another fluid volume or movement pattern.

Pellets and Multiparticulate Systems

Multiparticulate systems divide a formulation among multiple smaller units rather than placing the complete formulation in one tablet or capsule core.

These units may include:

• coated pellets
• mini-tablets
• granules
• beads
• porous particles

Researchers may study whether multiple units produce a broader distribution, a different release profile, or lower unit-to-unit dependence than one large dosage form.

However, coating variation among particles can create complex release patterns that require measurement across the complete batch.

Particle Size and Surface Area

Reducing particle size generally increases surface area relative to mass, but the effect on peptide release depends on the surrounding formulation.

Particle size may influence:

• wetting
• dissolution
• aggregation
• powder flow
• content uniformity
• compression behavior
• analytical sampling

Very small particles may also aggregate or adhere to processing equipment, capsule surfaces, or filters.

Granulation

Granulation combines fine powders into larger granules using dry or liquid-assisted processing.

Granulation may change:

• powder flow
• content uniformity
• porosity
• mechanical strength
• disintegration
• peptide exposure to moisture or heat

Wet granulation can expose a peptide to liquid, mixing, drying, and temperature conditions that differ from those used in dry granulation or direct compression.

Drying Processes

Solid peptide formulations may involve spray drying, freeze drying, vacuum drying, tray drying, or other water-removal methods.

Drying can influence:

• residual water
• particle morphology
• porosity
• peptide aggregation
• excipient distribution
• reconstitution or dissolution behavior

A dry powder with acceptable appearance may still contain structural or chemical changes that require analytical measurement.

Porous Carriers

Peptide formulations may be loaded into porous particles or matrices with internal channels and surface area.

Porous carriers can affect:

• loading capacity
• water uptake
• release rate
• peptide adsorption
• protection from direct environmental contact
• analytical extraction

Strong adsorption may improve retention during storage while reducing release during dissolution testing.

Polymeric Matrices

A peptide can be dispersed or embedded in a polymeric matrix.

Release may then occur through:

• water penetration
• polymer swelling
• diffusion through pores
• polymer erosion
• matrix breakup
• changes in polymer charge

The measured release curve represents the combined effects of the peptide, polymer, dosage-form dimensions, and test environment.

Peptide-Polymer Interactions

Peptides may interact with polymers through charge, hydrogen bonding, hydrophobic association, or surface adsorption.

These interactions can change:

• peptide distribution
• release completeness
• aggregation
• dissolution
• analytical recovery
• stability during storage

A polymer described as protective in one system may retain another peptide too strongly or alter its analytical behavior.

Layered Tablets

A layered tablet can physically separate formulation components until water enters the dosage form or the layers begin to erode.

Layering may be used to investigate:

• separation of incompatible ingredients
• sequential release
• local pH modification
• delayed contact between the peptide and another component
• different release rates from separate regions

Layer boundaries, compression, material movement, and manufacturing variation can affect whether the intended sequence is maintained.

Co-Located Release

Some solid systems are designed so that the peptide and another formulation component are released within a similar time and location.

Researchers may examine whether:

• both components dissolve at comparable rates
• one component diffuses away earlier
• local concentration is maintained
• the peptide remains stable in the shared microenvironment
• the components interact before release

Including two components in the same tablet does not establish that they reach the same region at the same concentration.

Microenvironmental pH

A solid dosage form may contain acidic, basic, or buffering components intended to create a local pH different from the bulk surrounding medium.

Microenvironmental pH can affect:

• peptide charge
• peptide solubility
• enzyme activity
• polymer behavior
• excipient ionization
• release

The local pH inside a hydrating tablet may not match the pH measured in the larger dissolution vessel.

Wetting

Before dissolution can occur, gastrointestinal fluid or test medium must contact and spread across the solid material.

Wetting may be affected by:

• surface composition
• particle size
• porosity
• lipid content
• surfactants
• compression
• coatings

Poor wetting can delay disintegration or create regions in which peptide-containing material remains dry.

Precipitation After Release

A peptide or peptide-associated complex may dissolve within the dosage form’s local environment and precipitate after entering a larger fluid volume.

Precipitation may occur because of changes in:

• pH
• ionic strength
• counterion concentration
• surfactant concentration
• cosolvent concentration
• temperature

Measuring only the amount that initially leaves the solid matrix may overstate the fraction that remains dissolved later in the test.

Solidification of Lipid Formulations

Liquid or semi-solid lipid systems can be converted into powders, granules, pellets, or tablets through adsorption, drying, or incorporation into carriers.

Solidification can change:

• dispersion time
• droplet formation
• peptide location
• lipid digestion
• release
• storage behavior

The final solid system must be evaluated independently rather than assuming it retains every property measured in the original liquid formulation.

Dosage-Form Geometry

Shape and dimensions influence how much surface is exposed to fluid and how far fluid must travel into the dosage form.

Geometry may affect:

• water penetration
• swelling
• erosion
• disintegration
• diffusion distance
• release duration

Two formulations with the same composition but different shapes or dimensions may produce different release profiles.

Dissolution Apparatus

Laboratory dissolution studies use controlled vessels, media, temperature, and movement to compare dosage forms.

Results can depend on:

• apparatus design
• agitation speed
• fluid volume
• sampling method
• medium composition
• pH transitions
• sink conditions

Dissolution data should therefore report the method in enough detail for the experiment to be interpreted and repeated.

Peptide-Specific Analytical Methods

Measuring total protein-like material is not always sufficient to determine how much intact peptide was released.

Analytical methods may need to distinguish:

• intact peptide
• degradation products
• aggregates
• peptide bound to particles
• peptide adsorbed to equipment
• unreleased peptide remaining in the dosage form

Apparent incomplete release may reflect analytical recovery problems, while apparent complete release may include altered peptide forms.

Storage Conditions

Solid dosage forms can change during storage because of humidity, temperature, oxygen, light, vibration, and interactions among components.

Storage studies may examine:

• peptide purity
• water content
• tablet hardness
• capsule-shell properties
• coating integrity
• disintegration
• dissolution and release

A formulation that meets release specifications when freshly prepared may behave differently after storage.

Published Research on Oral Peptide Formulations

A review available through the National Library of Medicine describes solid carriers, polymers, coatings, lipid systems, and other formulation approaches studied for oral peptide and protein delivery. The review also emphasizes that peptide-excipient interactions and gastrointestinal barriers must be considered when interpreting formulation findings.

Such reviews summarize multiple technologies, but each solid dosage form still requires evaluation using its exact peptide, excipients, manufacturing process, and release method.

Release and Permeability Must Not Be Combined into One Result

A solid dosage form may release most of its peptide while the peptide shows limited movement across a permeability model.

Another dosage form may release a smaller fraction but keep that fraction available near a selected experimental barrier.

This distinction is examined further in why dissolution and permeability must be studied separately.

What Solid Dosage-Form Testing May Establish

A solid dosage-form study may establish that a selected system:

• remains intact under specified conditions
• disintegrates within a measured period
• releases a measured peptide fraction
• changes release after a pH transition
• produces a reproducible laboratory profile
• retains selected properties after storage

What Solid Dosage-Form Testing Does Not Establish

Release testing alone does not establish:

• complete dissolution of intact peptide
• protection throughout gastrointestinal transit
• movement through mucus
• epithelial permeability
• reproducible measured exposure
• equivalence between dosage forms
• performance outside the tested conditions

Final Perspective

Solid dosage forms can control the physical arrangement, protection, wetting, disintegration, and release of peptide formulations.

The final release pattern results from interactions among the peptide, dosage-form geometry, polymers, coatings, fillers, compression, water uptake, pH, manufacturing process, and storage conditions.

Accurate evaluation should identify the solid format, peptide form, manufacturing method, disintegration behavior, dissolution method, intact-peptide recovery, release completeness, precipitation, and evidence stage rather than treating tablet or capsule breakup as proof of successful peptide delivery.